Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

17OHP-C Dosing Among Obese Pregnant Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03433040
Recruitment Status : Active, not recruiting
First Posted : February 14, 2018
Last Update Posted : November 5, 2019
Washington University School of Medicine
Information provided by (Responsible Party):
Anthony Odibo MD, University of South Florida

Brief Summary:
Emergency data suggest 17OHP-C may be less efficacious in obese women. Since obesity is associated with lower levels of plasma 17OHP-C, the investigator hypothesize that higher doses of 17OHP-C may help to prevent spontaneous PTB among obese women. The study aims to compare the pharmacokinetics of 17 OHP-C in obese compared with non-obese women.

Condition or disease Intervention/treatment Phase
Premature Birth Absorption; Chemicals Drug: 17-Hydroxyprogesterone Capronate Phase 3

Detailed Description:

Prospective three arm study of women with a prior spontaneous PTB. Non-obese women will receive the standard 250 mg weekly dose of 17 OHP-C while obese women will be randomly assigned to the standard (250 mg) or higher dose (500 mg). The resulting three groups will consist of:

  1. Normal weight women on 250mg 17OHPC
  2. Obese women on 250mg 17OHPC
  3. Obese women on 500mg of 17OHPC

Initial Enrollment: Pregnant patients receiving prenatal care at one of the USF affiliated sites or Washington University in St. Louis sites who report a history of a PTB will be approached by the research nurse. The research nurse will explain the study, review inclusion/exclusion criteria with the patient, and invite interested potential study candidates to sign a medical records release so that records from the previous PTB can be reviewed. If the medical records confirm the birth of a previous PTB was of a live born singleton gestation between the gestational ages of 20 weeks and 36 weeks and 6 days then the patient will be invited to participate in the study. At that time the informed consent form will be thoroughly reviewed with the patient, and if the patient desires to enroll, the patient will provide informed consent to enroll in the study. Consecutive women with normal BMI or obese women meeting the inclusion criteria will be approached to avoid selection bias.

Randomization: will occur at the time of enrollment. The randomization will be computer generated. Randomization envelopes indicating the randomization arm will be prepared ahead of time and the next consecutive envelope will be used at time of enrollment.

Pharmacokinetic studies: Sampling schedule in order to investigate the pharmacokinetics of 250 mg 17OHP-C weekly as compared to 500 mg 17OHP-C weekly in obese women as well as 250 mg in non-obese women will be performed as follows:

- Using principles described by Caritis et al., four completed weeks of 17OHP-C therapy is required prior to sampling anticipating that steady state will be achieved by this time point.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Impact of a Higher Dose on the Pharmacokinetics of 17-alpha Hydroxyprogesterone Caproate in Obese Women
Actual Study Start Date : August 23, 2017
Estimated Primary Completion Date : August 23, 2020
Estimated Study Completion Date : August 23, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
non obese
250mg 17 OHP-C
Drug: 17-Hydroxyprogesterone Capronate
17-Hydroxyprogesterone Capronate 250mg versus 500mg

obese - control
250mg 17 OHP-C
Drug: 17-Hydroxyprogesterone Capronate
17-Hydroxyprogesterone Capronate 250mg versus 500mg

Experimental: obese
500mg 17 OHP-C
Drug: 17-Hydroxyprogesterone Capronate
17-Hydroxyprogesterone Capronate 250mg versus 500mg

Primary Outcome Measures :
  1. Change in mean trough levels of 17-OHPC in the three groups at 20-22 weeks, 27-29 weeks and 34-36 weeks. [ Time Frame: From enrollment to 36 weeks of pregnancy ]
    Blood levels

Secondary Outcome Measures :
  1. Preterm birth <37, 34, 32, 28 weeks [ Time Frame: Up to 37 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • - Pregnant women, with a singleton gestation
  • Ages 18 - 55
  • Able to read and write in English and / or Spanish
  • History of spontaneous PTB
  • Obesity (≥ 30 kg / m2 ) vs non-obese groups (18 - 29.9 kg / m2 ) defined by first documented body mass index at an office visit
  • Gestational age between 12 weeks, 0 days and 24 weeks, 6 days of gestation
  • An ultrasound before 24 + 6 weeks gestation to confirm dating and to rule out major fetal anomalies
  • Willing to have weekly injections at the physician's office
  • The newborn will be enrolled on the mothers consent for chart review only

Exclusion Criteria:

  • - Multifetal gestation
  • Known fetal anomaly
  • Current progesterone treatment
  • Known or suspected breast cancer, other hormone-sensitive cancer, or history of these conditions
  • Current or history of thrombosis or thromboembolic disorder
  • Current anticoagulation
  • Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
  • Cholestatic jaundice of pregnancy
  • Liver tumors, benign or malignant, or active liver disease
  • uncontrolled hypertension (controlled hypertension is eligible)
  • A seizure disorder
  • Current or planned cervical cerclage
  • Plan to deliver elsewhere

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03433040

Layout table for location information
United States, Florida
University of South Florida
Tampa, Florida, United States, 33606
United States, Missouri
Washington University in St Louis
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
University of South Florida
Washington University School of Medicine
Layout table for investigator information
Principal Investigator: Anthony O Odibo, MD University of South Florida

Layout table for additonal information
Responsible Party: Anthony Odibo MD, Director Ultrasound and Fetal Therapy, University of South Florida Identifier: NCT03433040    
Other Study ID Numbers: 00026055
First Posted: February 14, 2018    Key Record Dates
Last Update Posted: November 5, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
17 alpha-Hydroxyprogesterone Caproate
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs